Global Anaemia Drugs Market Report and Forecast 2024-2032

Global Anaemia Drugs Market Outlook

The global anaemia drugs market is expected to grow at a CAGR of 8% in the forecast period of 2024-2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Increase in Kidney Diseases to Aid the Market Growth of Anaemia Drugs

The market growth of anaemia drugs is being driven by the significant contribution by North America to the global market. This could be attributed to the increase in incidence of the condition, increase in kidney diseases, and unhealthy lifestyle across the region. In addition, rise in health care expenditure, high research activities, advanced technology, and increasing awareness about anaemia are predicted to bolster the anaemia drugs industry in the region. Europe is expected to follow North America, in terms of contribution to the overall market growth. The market in the Asia Pacific is predicted to grow rapidly over the forecast period as the result of rising healthcare expenditure, surge in disposable income, rise in geriatric population, increase in awareness, high prevalence of chronic diseases, and complications during pregnancy in many developing countries.

Anaemia Drugs: Market Segmentation

Anaemia is a medical condition in which red blood cell (RBC) count or haemoglobin is less than normal. Anaemia results in shortness of breath, fatigue, palpitations, and dizziness. Anaemic drugs are used in the treatment of this condition.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

On the basis of anaemia type, the market is divided into:

• Iron Deficiency
• CKD (Chronic Kidney Disease)
• Sickle Cell
• Aplastic
• Others

Based on drugs, the industry can be segmented into:

• Dietary Supplements
• Medicines

The dietary supplements are further divided on the basis of types into iron supplements and vitamin supplements, among others, whereas medicines are further divided into antibiotics, hormones (erythropoietin), chelation therapy (lead poisoning), among others.

By distribution channel, the industry is categorised into:

• Hospital Pharmacy
• Store Pharmacy
• Online
• Others

The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Rising Prevalence of Anaemia to Aid the Market Growth of Anaemia Drugs

The market growth of anaemia drugs is being driven by the rising prevalence of this condition in children and women. In addition, factors such as unhealthy lifestyle, high number of women of reproductive age, development of pipeline products, and complications during pregnancy, especially in developing countries are expected to provide impetus over the forecast period. Further, rise in geriatric population, enhancing healthcare infrastructure, and rapid R&D are expected to fuel the market growth over the forecast period. However, factors like lack of awareness about health in many developing countries and expensive drugs are anticipated to hinder the market growth of anaemia drugs over the forecast period.

Key Industry Players in the Global Anaemia Drugs Market

The report gives a detailed analysis of the following key players in the global anaemia drugs market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

• Amgen Inc.
• Pieris Pharmaceuticals, Inc.
• Pfizer Inc.
• Akebia Therapeutics, Inc.
• Takeda Pharmaceutical Company Limited
• Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

Key Highlights of the Report